Highlights

  • Medical Developments International (ASX:MVP) gained 8.7% as its FY26 cash-flow profile improved.
  • The company reported positive free Cash Flow for both Q4 and the full financial year.
  • Full-year Penthrox Revenue increased by about AUD 5.4mn.
  • Australian hospital Penthrox volumes grew 28%, while European in-market volumes rose 18%.

Medical Developments International (ASX:MVP) has gained 8.7% as Penthrox growth begins translating more clearly into cash generation. The June-quarter update showed positive free cash flow for both Q4 and FY26, alongside higher pain-management revenue and expanding Penthrox volumes in Australia and Europe. The improvement gives the healthcare group a more balanced story heading into full-year results, with revenue growth now accompanied by better operating cash performance.

Penthrox Remains the Main Growth Engine

Full-year Penthrox revenue increased by approximately AUD 5.4mn compared with the prior year. Australian hospital volumes rose 28%, while European in-market Volume increased 18%.

Paediatric Approval Expands the Addressable Market

The company secured paediatric-label approval for Penthrox across the UK and EU, broadening the potential patient population and creating another commercialisation pathway.

Cash Flow Shows Operating Improvement

Medical Developments generated positive free cash flow for Q4 and the full year. Cash from Operating Activities was AUD 3.0mn in Q4, while the company ended June with AUD 21.4mn in cash.

What to Watch

FY26 EBIT, paediatric-launch execution, European Penthrox growth and performance of the Respiratory division are the main factors.

Risks

Penthrox growth must offset weaker areas of the portfolio. Regulatory, reimbursement, competitive and distributor execution risks remain.